Home | Welcome to Contract Pharma   
Last Updated Friday, November 21 2014
Print

Ark To Make Lymfactin for Laurantis



By Gil Roth



Published October 15, 2012
Related Searches: Manufacturing CDMO Pharma Clinical Trial
Ark Therapeutics has been selected to manufacture and supply Lymfactin to Laurantis Pharma under a conditional agreement announced today by the Finland-based companies. The agreement is subject to Laurantis receiving regulatory approval to commence its Phase I trial. Terms of the agreement were not disclosed.

Lymfactin uses an adenoviral vector to deliver vascular endothelial growth factor (VEGF-C) during transplantation of lymph nodes in order to avoid lymphedema. Ark is a CDMO focused on viral products, with R&D and GMP manufacturing in Finland and the UK

The Phase I clinical trial using Lymfactin to treat breast cancer-associated lymphedema is targeted to begin in 2013, and will recruit patients in the U.S. and Finland. Breast cancer-associated lymphedema is the most common form of secondary lymphedema, occurring in approximately 20% of breast cancer patients who undergo axillary lymph node dissection. The incidence is even higher in those who also receive radiotherapy, and this complication may even occur in those who undergo a lymph node biopsy as part of treatment. No therapeutic treatment currently exists to treat this disease.

In the U.S., approximately 110,000 patients are living with breast cancer-associated lymphedema, and nearly 15,000 new patients develop the complication each year. The number of lymphedema patients in Europe is estimated to be roughly the same as in the U.S.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On